Episurf Medical (NASDAQ: EPIS B) will presents its 2017 results, a business update and global opportunities on February 23. The presentation starts at 09:00 and will be available via webcast at www.redeye.se. At 11:00 the same day, the company invites investors to a presentation at Redeye, Mäster Samuelsgatan 42, Stockholm. Registration takes place at www.redeye.se or by using the link below. Episurf Medical will be represented by CEO Pål Ryfors and Katarina Flodström, project leader for the company’s US launch.
The company also announces that as of the report for the fourth quarter 2017, it will start publicizing the development of the company’s order book.
Register for the event: https://www.lyyti.fi/reg/Episurf__kvartalsuppdatering_hos_Redeye_6038
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.